Addex Therapeutics announced its spin-out, Neurosterix, secured $105 million in Series B funding. This financing validates Neurosterix's allosteric modulator approach for neuropsychiatric disorders and significantly increases the value of Addex's retained equity stake, providing a positive, albeit indirect, financial boost to Addex.
Addex Therapeutics reported that its spin-out company, Neurosterix, successfully closed a $105 million Series B financing round. This event is significant because it provides substantial capital for Neurosterix to advance its lead schizophrenia drug candidate, NTX-253, into Phase 2 clinical trials, as well as develop its broader pipeline. For Addex, this means its 8.5% equity interest in Neurosterix is now valued at $18.6 million, representing a substantial increase in the value of its non-core asset without any further investment. This development is positive for Addex as it validates its spin-out strategy and provides a clear valuation for a significant asset, potentially offering future monetization opportunities. The short-term implication is a positive sentiment boost for Addex, while the long-term opportunity lies in the potential for Neurosterix's pipeline success to further enhance the value of Addex's stake.